Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection

被引：36

作者：

Saleh-Mghir, A

Ameur, N

Muller-Serieys, C

Ismael, F

Lemaitre, F

Massias, L

Feger, C

Bléton, R

Crémieux, AC

机构：

[1] Hop Bichat Claude Bernard, INSERM, EMI, U9933, F-75877 Paris 18, France

[2] Aventis Pharma, Paris, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 04期

关键词：

D O I：

10.1128/AAC.46.4.1122-1124.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We compared the efficacies of quinupristin-dalfopristin (Q-D; 30 mg/kg of body weight every 8 h) and vancomycin (60 mg/kg twice daily), alone or in combination with rifampin (10 mg/kg twice daily), in a rabbit model of methicillin-resistant Staphylococcus aureus knee prosthesis infection. In contrast to vancomycin, Q-D significantly reduced the mean log(10) CFU per gram of bone versus that for the controls. The combination of rifampin with either Q-D or vancomycin was significantly more effective than monotherapy.

引用

收藏

页码：1122 / 1124

页数：3

相关论文

共 32 条

[1] Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus [J].

Aubry-Damon, H ;

Soussy, CJ ;

Courvalin, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2590-2594

[2] New model of experimental prosthetic joint infection due to methicillin-resistant Staphylococcus aureus: A microbiologic, histopathologic, and magnetic resonance imaging characterization [J].

Belmatoug, N ;

Cremieux, AC ;

Bleton, R ;

Volk, A ;

SalehMghir, A ;

Grossin, M ;

Garry, L ;

Carbon, C .

JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (02) :414-417

[3]

BENGTSON S, 1993, ANN MED, V25, P523

[4] Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus:: Evidence of resistance to vancomycin [J].

Burnie, J ;

Matthews, R ;

Jiman-Fatami, A ;

Gottardello, P ;

Hodgetts, S ;

D'arcy, S .

CLINICAL INFECTIOUS DISEASES, 2000, 31 (03) :684-689

[5] SUCCESSFUL THERAPY OF EXPERIMENTAL CHRONIC FOREIGN-BODY INFECTION DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS BY ANTIMICROBIAL COMBINATIONS [J].

CHUARD, C ;

HERRMANN, M ;

VAUDAUX, P ;

WALDVOGEL, FA ;

LEW, DP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (12) :2611-2616

[6] Efficacy of sparfloxacin and autoradiographic diffusion pattern of [C-14]sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection [J].

Cremieux, AC ;

Mghir, AS ;

Bleton, R ;

Manteau, M ;

Belmatoug, N ;

Massias, L ;

Garry, L ;

Sales, N ;

Maziere, B ;

Carbon, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2111-2116

[7]

Dowzicky Michael, 1998, American Journal of Medicine, V104, p34S, DOI 10.1016/S0002-9343(98)00153-3

[8] RIFAMPIN RESISTANCE - DEVELOPMENT DURING THE THERAPY OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS INFECTION [J].

ENG, RHK ;

SMITH, SM ;

TILLEM, M ;

CHERUBIN, C .

ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (01) :146-148

[9] TREATMENT OF EXPERIMENTAL ENDOCARDITIS DUE TO ERYTHROMYCIN-SUSCEPTIBLE OR ERYTHROMYCIN-RESISTANT METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS WITH RP-59500 [J].

ENTENZA, JM ;

DRUGEON, H ;

GLAUSER, MP ;

MOREILLON, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1419-1424

[10] CRITICAL INFLUENCE OF RESISTANCE TO STREPTOGRAMIN B-TYPE ANTIBIOTICS ON ACTIVITY OF RP-59500 (QUINUPRISTIN-DALFOPRISTIN) IN EXPERIMENTAL ENDOCARDITIS DUE TO STAPHYLOCOCCUS-AUREUS [J].

FANTIN, B ;

LECLERCQ, R ;

MERLE, Y ;

SAINTJULIEN, L ;

VEYRAT, C ;

DUVAL, J ;

CARBON, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :400-405

← 1 2 3 4 →